Supplementary Figure 12 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Eric Y. Stutheit-Zhao; Enrique Sanz‐García; Zhihui Amy Liu; Derek Wong; Kayla Marsh; Albiruni R. Abdul Razak; Anna Spreafico; Philippe L. Bédard; Aaron R. Hansen; Stéphanie Lheureux; Dax Torti; Bernard Lam; Shih Yu Cindy Yang; Justin Burgener; Ping Luo; Yong Zeng; Nicholas Cheng; Philip Awadalla; Scott V. Bratman; Pamela S. Ohashi; Trevor J. Pugh; Lillian L. Siu

doi:10.1158/2159-8290.25956888.v1

Abstract

Multivariate Cox analysis of change in cancer mutation concentration (CMC) from baseline to cycle 3 of pembrolizumab. Covariates include cohort, PD-L1 expression, and tumor mutation burden

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stutheit-Zhao et al. (2024) studied this question.

synapsesocial.com/papers/68e66839b6db6435875f3e9a https://doi.org/10.1158/2159-8290.25956888.v1

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure 12 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Abstract

Discussion

Cite This Study

Supplementary Figure 12 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers